Skye Bioscience Announces Special Virtual Investor Presentation

Skye Bioscience Investor Hour

Please join us for a special investor presentation.

SAN DIEGO, CA, Sept. 14, 2021 (GLOBE NEWSWIRE) —  Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will host a special virtual investor presentation on Tuesday, October 12. The filmed broadcast of this virtual event will be available beginning at 1 p.m. ET/10:00 a.m. PT. The agenda will include the company’s strategic direction and business outlook for 2022, clinical development updates on the company’s lead glaucoma program, R&D advancements and new initiatives, followed by Q&A. Speakers for this event will include Skye’s executive management team in addition to select members of its scientific and clinical advisory boards. Questions may be submitted for consideration for this special event to [email protected] on or before September 28, 2021.  All investors and analysts are requested to register in advance of the event. Registration is available via https://bit.ly/3lnmLO3 or via the Company’s Investor Relations website at  https://ir.skyebioscience.com/. About Skye BioscienceSkye Bioscience Inc. is a biopharmaceutical company unlocking the pharmaceutical potential of cannabinoids through the development of its proprietary, cannabinoid-derived molecules to treat diseases with significant unmet needs. The company’s lead program, THCVHS, is focused on treating glaucoma, the world’s leading cause of irreversible blindness. For more information, please visit: www.skyebioscience.com. CONTACTKaram Takhar VP, Corporate Development & Investor Relations Email: [email protected] Phone: (858) 410-0266 FORWARD LOOKING STATEMENTS This press release contains forward-looking statements, including statements regarding our product development, business strategy, timing of clinical trials and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
Attachment

Skye Bioscience Investor Hour